Clinical TrialMay 28, 2026, 09:18 AM
Akari Therapeutics CEO highlights ASCO data for AKTX-101 in KRAS cancers
AI Summary
Akari Therapeutics' CEO, Abizer Gaslightwala, discussed promising preclinical data at the 2026 ASCO Annual Meeting, highlighting the synergy of AKTX-101 with a KRAS inhibitor in KRAS-mutated pancreatic cancer models. This data validates the company's differentiated spliceosome-modulating ADC platform and its PH1 payload, which aims to redefine treatment for difficult-to-treat KRAS-driven cancers. The company also outlined plans to initiate a Phase 1 first-in-human clinical trial for AKTX-101 by mid-2027.
Key Highlights
- Akari Therapeutics CEO presented promising preclinical data at 2026 ASCO Annual Meeting.
- Data showed AKTX-101 synergy with a KRAS inhibitor in KRAS-mutated pancreatic cancer models.
- ASCO abstract acceptance validates Akari's differentiated ADC platform and PH1 payload.
- PH1 payload platform targets difficult-to-treat KRAS-driven tumors.
- Company aims to initiate Phase 1 first-in-human clinical trial for AKTX-101 by mid-2027.
- AKTX-101 is a lead candidate targeting Trop2 receptor with a novel PH1 spliceosome modulator.
Price Impact
More from AKTX